Clinical data at diagnosis
| . | CIMF-0 . | CIMF-1 . | CIMF-2 . | CIMF-3 . | PPMM . |
|---|---|---|---|---|---|
| No. of patients | 33 | 27 | 26 | 12 | 15 |
| Median age, y (range) | 66 (27–80) | 67 (29–84) | 71 (45–86) | 71 (60–85) | 64 (45–85) |
| M/F, ratio | 16/17 (0.94) | 14/13 (1.08) | 16/10 (1.6) | 7/5 (1.4) | 8/7 (1.14) |
| Hb level, g/L, median (range) | 139 (68–170) | 118 (76–167) | 116 (62–163) | 105 (76–141) | 116 (88–153) |
| Hb level less than 100 g/L, no. of pts (%) | 1 (3) | 7 (26) | 11 (42) | 5 (42) | 4 (27) |
| Plt count, ×109/L, median (range) | 746 (289–1546) | 521 (4–1289) | 430 (88–1470) | 187 (17–489) | 282 (31–903) |
| Plt count less than 100×109/L, no. of pts (%) | 0 (0) | 3 (11) | 2 (8) | 3 (25) | 2 (13) |
| WBC count, ×109/L, median (range) | 9.5 (5.9–41.6) | 7.6 (1.9–20.6) | 10.8 (1.9–25.2) | 9.8 (1.9–39.4) | 8.9 (2.8–34) |
| WBC count less than 4 or higher than 30×109/L, no. of pts (%) | 1 (3) | 2 (7) | 3 (11) | 2 (17) | 2 (13) |
| AMC 1×109/L or higher, no. of pts (%) | 5 (15) | 1 (4) | 3 (11) | 2 (17) | 1 (7) |
| Circulating blasts 1% or more, no. of pts (%) | 4 (12) | 7 (26) | 14 (54) | 7 (58) | 9 (60) |
| Constitutional symptoms, no. of pts (%) | 0 (0) | 3 (11) | 3 (11) | 1 (8) | 1 (7) |
| No. of deaths (%) | 0 (0) | 3 (11) | 4 (15) | 6 (50) | 2 (13) |
| Mayo PSS,12 no. of pts (%) | |||||
| LR | 28 (85) | 20 (74) | 12 (46) | 4 (33) | 10 (67) |
| IR | 4 (12) | 2 (7) | 11 (42) | 4 (33) | 2 (13) |
| HR | 1 (3) | 5 (19) | 3 (12) | 4 (33) | 3 (20) |
| Dingli PSS,12 no. of pts (%) | |||||
| LR | 33 (100) | 20 (74) | 15 (58) | 5 (42) | 10 (67) |
| IR | 0 (0) | 3 (11) | 8 (31) | 4 (33) | 3 (20) |
| HR | 0 (0) | 4 (15) | 3 (11) | 3 (25) | 2 (13) |
| Cervantes PSS,10 no. of pts (%) | |||||
| LR | 33 (100) | 24 (89) | 18 (69) | 8 (67) | 11 (73) |
| HR | 0 (0) | 3 (11) | 8 (31) | 4 (33) | 4 (27) |
| Dupriez PSS,11 no. of pts (%) | |||||
| LR | 32 (97) | 20 (74) | 15 (58) | 6 (50) | 10 (67) |
| IR | 0 (0) | 5 (19) | 8 (31) | 5 (42) | 4 (27) |
| HR | 1 (3) | 2 (7) | 3 (11) | 1 (8) | 1 (6) |
| . | CIMF-0 . | CIMF-1 . | CIMF-2 . | CIMF-3 . | PPMM . |
|---|---|---|---|---|---|
| No. of patients | 33 | 27 | 26 | 12 | 15 |
| Median age, y (range) | 66 (27–80) | 67 (29–84) | 71 (45–86) | 71 (60–85) | 64 (45–85) |
| M/F, ratio | 16/17 (0.94) | 14/13 (1.08) | 16/10 (1.6) | 7/5 (1.4) | 8/7 (1.14) |
| Hb level, g/L, median (range) | 139 (68–170) | 118 (76–167) | 116 (62–163) | 105 (76–141) | 116 (88–153) |
| Hb level less than 100 g/L, no. of pts (%) | 1 (3) | 7 (26) | 11 (42) | 5 (42) | 4 (27) |
| Plt count, ×109/L, median (range) | 746 (289–1546) | 521 (4–1289) | 430 (88–1470) | 187 (17–489) | 282 (31–903) |
| Plt count less than 100×109/L, no. of pts (%) | 0 (0) | 3 (11) | 2 (8) | 3 (25) | 2 (13) |
| WBC count, ×109/L, median (range) | 9.5 (5.9–41.6) | 7.6 (1.9–20.6) | 10.8 (1.9–25.2) | 9.8 (1.9–39.4) | 8.9 (2.8–34) |
| WBC count less than 4 or higher than 30×109/L, no. of pts (%) | 1 (3) | 2 (7) | 3 (11) | 2 (17) | 2 (13) |
| AMC 1×109/L or higher, no. of pts (%) | 5 (15) | 1 (4) | 3 (11) | 2 (17) | 1 (7) |
| Circulating blasts 1% or more, no. of pts (%) | 4 (12) | 7 (26) | 14 (54) | 7 (58) | 9 (60) |
| Constitutional symptoms, no. of pts (%) | 0 (0) | 3 (11) | 3 (11) | 1 (8) | 1 (7) |
| No. of deaths (%) | 0 (0) | 3 (11) | 4 (15) | 6 (50) | 2 (13) |
| Mayo PSS,12 no. of pts (%) | |||||
| LR | 28 (85) | 20 (74) | 12 (46) | 4 (33) | 10 (67) |
| IR | 4 (12) | 2 (7) | 11 (42) | 4 (33) | 2 (13) |
| HR | 1 (3) | 5 (19) | 3 (12) | 4 (33) | 3 (20) |
| Dingli PSS,12 no. of pts (%) | |||||
| LR | 33 (100) | 20 (74) | 15 (58) | 5 (42) | 10 (67) |
| IR | 0 (0) | 3 (11) | 8 (31) | 4 (33) | 3 (20) |
| HR | 0 (0) | 4 (15) | 3 (11) | 3 (25) | 2 (13) |
| Cervantes PSS,10 no. of pts (%) | |||||
| LR | 33 (100) | 24 (89) | 18 (69) | 8 (67) | 11 (73) |
| HR | 0 (0) | 3 (11) | 8 (31) | 4 (33) | 4 (27) |
| Dupriez PSS,11 no. of pts (%) | |||||
| LR | 32 (97) | 20 (74) | 15 (58) | 6 (50) | 10 (67) |
| IR | 0 (0) | 5 (19) | 8 (31) | 5 (42) | 4 (27) |
| HR | 1 (3) | 2 (7) | 3 (11) | 1 (8) | 1 (6) |
CIMF indicates chronic idiopathic myelofibrosis; PPMM, postpolycythemic myelofibrosis and myeloid metaplasia; Hb, hemoglobin; Plt, platelet; WBC, white blood cell; AMC, absolute monocyte count; PSS, prognostic scoring system; LR, low risk; IR, intermediate risk; and HR, high risk.